Director James E. Dentzer of Imunon, Inc. reported an acquisition of common stock on November 10, 2026, covering a transaction dated November 6, 2026, in a statement of changes in beneficial ownership filed with the SEC.

Key Highlights

  • Shares acquired: James E. Dentzer received 13,166 shares of Imunon, Inc. common stock on November 6, 2026.
  • Price per share: The shares were recorded at $0.845 each, according to the filing.
  • Nature of grant: The filing states the stock was "granted in lieu of cash for portion of board fees."
  • Resulting ownership: Following the transaction, Dentzer directly held 34,197 shares of Imunon common stock.
  • Transaction code: The acquisition was coded "A" (acquired) in the filing, with no derivative securities reported.
  • Signing authority: The filing was signed by Jeffrey W. Church as attorney-in-fact for James Dentzer on November 10, 2026.

Dentzer Board Fee Settlement in Imunon Common Stock

According to the filing, James E. Dentzer, identified as a director of Imunon, Inc. (NASDAQ:IMNN), acquired 13,166 shares of the company's common stock on November 6, 2026. The filing's footnote explains that the shares were "granted in lieu of cash for portion of board fees," indicating the transaction reflects a compensation arrangement rather than an open-market purchase. The price associated with the grant was listed as $0.845 per share.

Imunon, Inc. is a clinical-stage biopharmaceutical company. The director's beneficial ownership of common stock, held directly, totaled 34,197 shares following the reported transaction. No derivative securities were reported in Table II of the filing. The statement was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and significant shareholders to disclose changes in their holdings. Jeffrey W. Church signed the form as attorney-in-fact for Dentzer on November 10, 2026.

What Was Disclosed

The filing disclosed that Imunon director James E. Dentzer acquired 13,166 shares of common stock at $0.845 per share on November 6, 2026, as stock granted in lieu of cash board fees, bringing his direct beneficial ownership to 34,197 shares.